MedTrace Logo

The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening.

NCT02618538 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26600

Last updated 2019-07-23

No results posted yet for this study

Summary

Some women have a higher risk than others of developing breast cancer. Unhealthy lifestyles, high breast density, family history, obesity, the presence of biomarkers associated with early neoplastic changes (considered alone or in combination) are just some of main factors that can increase the risk of breast cancer. Women with a higher risk may need to undergo more intensive screening activities, which include more frequent inspections and the possibility of experiment different types of tests. Instead, low risk women could be screened at longer intervals in order to reduce the screening harms (false positive results, overdiagnosis, radiation exposure, discomfort caused by the test itself, etc.) The ANDROMEDA Study aims at creating the possibility to customize the screening paths through a combined analysis of the above mentioned risk factors. Women consenting to be involved in the study will be asked to provide information on their lifestyle habits and reproductive history. Furthermore a blood sample will be collected for further bio-molecular analysis purposes.

Conditions

Sponsors & Collaborators

  • Azienda Sanitaria Locale di Biella

    collaborator OTHER

  • Azienda Sanitaria Locale di Vercelli

    collaborator OTHER

  • Fondazione Edo Ed Elvo Tempia Valenta

    collaborator OTHER

  • Associazione Italiana per la Ricerca sul Cancro

    collaborator OTHER

  • Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

    lead OTHER

Principal Investigators

  • Nereo Segnan, MD MSc Epi · Structure director

Eligibility

Min Age
46 Years
Max Age
67 Years
Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02618538 on ClinicalTrials.gov